Tang Capital
View Older Stories View More Recent Stories
-
Concerned Shareholder Group Calls for Atea Pharmaceuticals to Appoint a New, Shareholder-Oriented Lead Independent Director to Oversee Strategic Review Process
-
Form SC 13G CYBIN INC. Filed by: TANG CAPITAL MANAGEMENT LLC
-
Form SC 13G Journey Medical Corp Filed by: TANG CAPITAL MANAGEMENT LLC
-
Form SC 13G LianBio Filed by: TANG CAPITAL MANAGEMENT LLC
-
Form SC 13G/A BioAtla, Inc. Filed by: TANG CAPITAL MANAGEMENT LLC
-
Form 13F-HR TANG CAPITAL MANAGEMENT For: Sep 30
-
Form SC 13G/A KalVista Pharmaceuticals Filed by: TANG CAPITAL MANAGEMENT LLC
-
Form SC 13G/A PRECISION BIOSCIENCES Filed by: TANG CAPITAL MANAGEMENT LLC
-
Form SC 13G/A Evolus, Inc. Filed by: TANG CAPITAL MANAGEMENT LLC
-
Form SC 13G/A CytomX Therapeutics, Filed by: TANG CAPITAL MANAGEMENT LLC
-
Form SC 13G/A LENZ Therapeutics, Inc. Filed by: TANG CAPITAL MANAGEMENT LLC
-
Form SC 13G/A OnKure Therapeutics, Filed by: TANG CAPITAL MANAGEMENT LLC
-
Form SC 13G/A Adicet Bio, Inc. Filed by: TANG CAPITAL MANAGEMENT LLC
-
Form SC 13G/A Quince Therapeutics, Filed by: TANG CAPITAL MANAGEMENT LLC
-
Form SC 13G/A Corbus Pharmaceuticals Filed by: TANG CAPITAL MANAGEMENT LLC
-
Form SC 13G/A ANAPTYSBIO, INC Filed by: TANG CAPITAL MANAGEMENT LLC
-
Form SC 13D ESSA Pharma Inc. Filed by: TANG CAPITAL MANAGEMENT LLC
-
Form SC 13G Monopar Therapeutics Filed by: TANG CAPITAL MANAGEMENT LLC
-
H.C. Wainwright Reiterates Neutral Rating on Kezer Life Sciences (KZR)
-
Kezar Life Sciences (KZR) Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal
-
Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal
-
Kezar Life Sciences (KZR) Shareholder Kevin Tang Offers to Acquire 100% of Company for $1.10 Per Share Plus CVR
-
Form SC 13D Kezar Life Sciences, Filed by: TANG CAPITAL MANAGEMENT LLC
-
Form SC 13G iTeos Therapeutics, Inc. Filed by: TANG CAPITAL MANAGEMENT LLC
-
Form SC 13G Reneo Pharmaceuticals, Filed by: TANG CAPITAL PARTNERS LP
-
Singular Genomics Receives Non-Binding Acquisition Proposal from Concentra Biosciences and Tang Capital
-
Singular Genomics Systems (OMIC) receives $12 per share offer from Kevin Tang
-
Form 4 Singular Genomics System For: Sep 16 Filed by: TANG CAPITAL PARTNERS LP
-
Form 3 Singular Genomics System For: Sep 16 Filed by: TANG CAPITAL PARTNERS LP
-
Form SC 13D Singular Genomics System Filed by: TANG CAPITAL MANAGEMENT LLC
-
Form SC 13D Aurinia Pharmaceuticals Filed by: TANG CAPITAL MANAGEMENT LLC
-
Aurinia Pharmaceuticals (AUPH) Announces Board Restructuring
-
Aurinia Announces Board Restructuring
-
Form N-PX TANG CAPITAL MANAGEMENT For: Jun 30
-
Form SC 13G ALX ONCOLOGY HOLDINGS Filed by: TANG CAPITAL PARTNERS LP
-
Form 13F-HR TANG CAPITAL MANAGEMENT For: Jun 30
-
Form SC 13G HilleVax, Inc. Filed by: TANG CAPITAL PARTNERS LP
-
Form SC 13G AGILE THERAPEUTICS INC Filed by: TANG CAPITAL PARTNERS LP
-
Form 13F-HR TANG CAPITAL MANAGEMENT For: Mar 31
-
Form SC 13G MARINUS PHARMACEUTICALS, Filed by: TANG CAPITAL PARTNERS LP
-
Form SC 13G Outlook Therapeutics, Filed by: TANG CAPITAL PARTNERS LP
-
Form SC 13D/A Theseus Pharmaceuticals, Filed by: TANG CAPITAL PARTNERS LP
-
Form 4 TCR2 THERAPEUTICS INC. For: Jun 01 Filed by: TANG CAPITAL PARTNERS LP
-
Form SC 13G/A InflaRx N.V. Filed by: TANG CAPITAL PARTNERS LP
-
Form SC 13G/A KalVista Pharmaceuticals Filed by: TANG CAPITAL PARTNERS LP
-
Form SC 13G/A Adicet Bio, Inc. Filed by: TANG CAPITAL PARTNERS LP
-
Form SC 13G/A ANAPTYSBIO, INC Filed by: TANG CAPITAL PARTNERS LP
-
Form SC 13G/A Transcode Therapeutics, Filed by: TANG CAPITAL PARTNERS LP
-
Form SC 13G/A TCR2 THERAPEUTICS INC. Filed by: TANG CAPITAL PARTNERS LP
-
Form SC 13G/A Quince Therapeutics, Filed by: TANG CAPITAL PARTNERS LP

